GEP20257823B - Amino quinazoline derivatives as p2x3 inhibitors - Google Patents

Amino quinazoline derivatives as p2x3 inhibitors

Info

Publication number
GEP20257823B
GEP20257823B GEAP202015818A GEAP2020015818A GEP20257823B GE P20257823 B GEP20257823 B GE P20257823B GE AP202015818 A GEAP202015818 A GE AP202015818A GE AP2020015818 A GEAP2020015818 A GE AP2020015818A GE P20257823 B GEP20257823 B GE P20257823B
Authority
GE
Georgia
Prior art keywords
inhibitors
quinazoline derivatives
amino quinazoline
amino
receptors
Prior art date
Application number
GEAP202015818A
Other languages
English (en)
Inventor
Kim Louise Hirst
De Poël Hervè Van
Charles Baker-Glenn
Paolo Ronchi
Daniele Pala
Daniela Pizzirani
Klaudio Fiorelli
Matteo Biagetti
Paolo Bruno
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of GEP20257823B publication Critical patent/GEP20257823B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
GEAP202015818A 2019-05-31 2020-05-28 Amino quinazoline derivatives as p2x3 inhibitors GEP20257823B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19177604 2019-05-31
EP19201168 2019-10-02

Publications (1)

Publication Number Publication Date
GEP20257823B true GEP20257823B (en) 2025-11-10

Family

ID=70861506

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202015818A GEP20257823B (en) 2019-05-31 2020-05-28 Amino quinazoline derivatives as p2x3 inhibitors
GEAP202515818A GEAP202515818A (en) 2019-05-31 2020-05-28 Amino quinazoline derivatives as p2x3 inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
GEAP202515818A GEAP202515818A (en) 2019-05-31 2020-05-28 Amino quinazoline derivatives as p2x3 inhibitors

Country Status (20)

Country Link
US (2) US20230092892A1 (enExample)
EP (2) EP3976180A1 (enExample)
JP (3) JP7641917B2 (enExample)
KR (2) KR20220016499A (enExample)
CN (3) CN113891745B (enExample)
AU (2) AU2020281923A1 (enExample)
BR (2) BR112021022099A2 (enExample)
CA (2) CA3139019A1 (enExample)
CL (1) CL2021003165A1 (enExample)
CO (1) CO2021017031A2 (enExample)
GE (2) GEP20257823B (enExample)
IL (1) IL288405A (enExample)
MA (2) MA56021A (enExample)
MX (2) MX2021014113A (enExample)
PE (1) PE20220934A1 (enExample)
PH (1) PH12021552881A1 (enExample)
SA (1) SA521430920B1 (enExample)
SG (1) SG11202112187YA (enExample)
WO (2) WO2020239952A1 (enExample)
ZA (1) ZA202108273B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021022099A2 (pt) * 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3
FI3976597T3 (fi) 2019-05-31 2024-09-25 Janssen Pharmaceutica Nv Nf-kb:tä indusoivan kinaasin pienimolekyylisiä estäjiä
CA3141826A1 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
BR112021020279A2 (pt) * 2019-05-31 2021-12-14 Chiesi Farm Spa Derivados de piridopirimidinas como inibidores de p2x3
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
WO2022083657A1 (zh) * 2020-10-20 2022-04-28 苏州泽璟生物制药股份有限公司 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
ES3026782T3 (en) * 2020-11-27 2025-06-12 Chiesi Farm Spa (aza)quinoline 4-amines derivatives as p2x3 inhibitors
AU2021388923A1 (en) * 2020-11-27 2023-05-25 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
CN112661803A (zh) * 2020-12-17 2021-04-16 上海药明康德新药开发有限公司 DNA编码化合物库构建中On-DNA 4-胺基喹唑啉化合物的合成方法
KR20230155422A (ko) * 2020-12-22 2023-11-10 메카니스틱 테라퓨틱스 엘엘씨 Egfr 및/또는 pi3k 억제제로서의 치환된 아미노벤질헤테로아릴 화합물
WO2022171118A1 (zh) * 2021-02-10 2022-08-18 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
CN115677601B (zh) * 2021-07-29 2025-06-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途
WO2024235225A1 (zh) * 2023-05-15 2024-11-21 苏州泽璟生物制药股份有限公司 取代嘧啶并环类抑制剂及其制备方法和应用
WO2024240728A1 (en) 2023-05-22 2024-11-28 Chiesi Farmaceutici S.P.A. Process and intermediates for the preparation of a p2x3 inhibitor
AR132741A1 (es) 2023-05-22 2025-07-23 Chiesi Farm Spa Sales de derivados de aminoquinazolina
WO2025101598A1 (en) * 2023-11-07 2025-05-15 Zeno Management, Inc. Bi-cyclic pyrimidine compounds, methods and uses thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
JP4342007B2 (ja) 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
BR122018003623B8 (pt) * 2004-03-05 2021-07-27 Hoffmann La Roche diaminopirimidinas, seus usos, e composição farmacêutica
ATE537169T1 (de) * 2005-08-15 2011-12-15 Hoffmann La Roche Piperidin- und piperazinderivate als p2x3- antagonisten
WO2007025925A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
WO2008000645A1 (en) 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Tetrazole-substituted arylamides
CA2682162C (en) 2007-04-02 2016-05-10 Renovis, Inc. Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
PL2139334T3 (pl) 2007-04-17 2013-11-29 Evotec Ag Skondensowane związki heterocykliczne 2-cyjanofenylu i ich kompozycje i zastosowania
MX2010009561A (es) 2008-02-29 2010-09-24 Renovis Inc Compuestos amida, composiciones y usos de los mismos.
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
AU2011326427B2 (en) 2010-11-10 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2014102233A1 (en) 2012-12-27 2014-07-03 F. Hoffmann-La Roche Ag Comt inhibitors
TWI637949B (zh) 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
US20170239249A1 (en) * 2014-09-30 2017-08-24 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
JPWO2016084922A1 (ja) 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
JPWO2016088838A1 (ja) 2014-12-04 2017-09-14 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
RS63014B1 (sr) 2014-12-09 2022-04-29 Bayer Ag 1,3-tiazol-2-il supstituisani benzamidi
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
LT3355889T (lt) 2015-09-29 2023-05-10 Afferent Pharmaceuticals Inc. Diaminopirimidino p2x3 ir p2x2/3 receptorių moduliatoriai, skirti panaudoti gydant kosulį
JP6882289B2 (ja) * 2015-11-25 2021-06-02 コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ 二環式ｂｅｔブロモドメイン阻害剤及びその使用
ES2800339T3 (es) 2016-06-30 2020-12-29 Gilead Sciences Inc 4,6-diaminoquinazolinas como moduladores de cuna y métodos de uso de los mismos
WO2018035061A1 (en) * 2016-08-15 2018-02-22 Neupharma, Inc. Certain chemical entities, compositions, and methods
US10898487B2 (en) * 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
GB201700814D0 (en) 2017-01-17 2017-03-01 Liverpool School Tropical Medicine Compounds
EP3619193B1 (en) * 2017-05-05 2023-03-22 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
BR112021020279A2 (pt) 2019-05-31 2021-12-14 Chiesi Farm Spa Derivados de piridopirimidinas como inibidores de p2x3
BR112021022099A2 (pt) * 2019-05-31 2021-12-28 Chiesi Farm Spa Derivados de amino quinazolina como inibidores de p2x3

Also Published As

Publication number Publication date
AU2020285336A1 (en) 2022-01-06
PH12021552881A1 (en) 2022-07-25
SG11202112187YA (en) 2021-12-30
CL2021003165A1 (es) 2022-09-23
PE20220934A1 (es) 2022-05-31
BR112021021738A2 (pt) 2021-12-28
JP7644029B2 (ja) 2025-03-11
EP3976180A1 (en) 2022-04-06
WO2020239951A1 (en) 2020-12-03
CN113891745A (zh) 2022-01-04
CO2021017031A2 (es) 2022-01-17
CN114269432A (zh) 2022-04-01
CA3139019A1 (en) 2020-12-03
BR112021022099A2 (pt) 2021-12-28
JP2025098014A (ja) 2025-07-01
CA3139018A1 (en) 2020-12-03
NZ782235A (en) 2025-03-28
CN118239931A (zh) 2024-06-25
US20220227749A1 (en) 2022-07-21
KR20220016499A (ko) 2022-02-09
US12466820B2 (en) 2025-11-11
AU2020281923A1 (en) 2022-01-06
IL288405A (en) 2022-01-01
EP3976179A1 (en) 2022-04-06
ZA202108273B (en) 2023-07-26
MX2021014115A (es) 2021-12-10
CN114269432B (zh) 2024-05-07
MX2021014113A (es) 2021-12-10
JP2022534303A (ja) 2022-07-28
WO2020239952A1 (en) 2020-12-03
GEAP202515818A (en) 2025-07-10
SA521430920B1 (ar) 2025-05-21
KR20220016498A (ko) 2022-02-09
JP2022534751A (ja) 2022-08-03
MA56022A (fr) 2022-04-06
MA56021A (fr) 2022-04-06
CN113891745B (zh) 2024-05-07
JP7641917B2 (ja) 2025-03-07
US20230092892A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
GEP20257823B (en) Amino quinazoline derivatives as p2x3 inhibitors
GEP20237561B (en) Protein tyrosine phosphatase inhibitors
SA520412278B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات جين أس أوه أس 1
PH12021550166A1 (en) Nlrp3 inflammasome inhibitors
PH12019501941A1 (en) Jak inhibitors containing a 4-membered heterocyclic amide
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
PH12014500529A1 (en) Substituted n- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin c
EA202190681A1 (ru) Амиды диметиламиноазетидина в качестве jak ингибиторов
EA202190686A1 (ru) 5-7-членные гетероциклические амиды в качестве ингибиторов jak
EA202090688A1 (ru) Бис-амидные соединения, активирующие саркомер, и варианты их применения
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
MX2021008510A (es) Derivados de tiazolopiridina como antagonistas del receptor de adenosina.
MX2020007985A (es) Inhibicion del canal ionico receptor de potencial transitorio a1.
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
MX2021015898A (es) Compuestos heterocíclicos bicíclicos como inhibidores de actividad de ofbcdin3d.
PH12021550258A1 (en) Cdk8/19 inhibitors
EP4620940A3 (en) Synthesis of (+)-cannabinoids and their therapeutic effects
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
MX2024003930A (es) Moduladores de trpml, sus composiciones y metodos de uso.
MX385475B (es) Derivados de piridoquinazolina eficaces como inhibidores de proteina quinasa
MX2022001516A (es) Antagonistas del receptor de neuropeptido ff.
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
GB2553685A8 (en) Novel éthynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis